Recently experts at the Harvard-affiliated Dana Farber Cancer tumor Institute in Boston have conducted a series of experiments that place tanning in a different light. A suntan, they say, may be the body’s best effort to fight the known cancerous effects of ultraviolet light, the invisible portion of the light spectrum that penetrates your skin and mutates DNA, the July 2007 issue of the Harvard Health Letter reviews. Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancers patientsFDA grants accelerated acceptance for Tagrisso to treat individuals with advanced NSCLCViralytics enters into scientific trial collaboration contract with MSDSo, if tans are protective, should we toss our SPF 45 and be sun worshippers? No.By AMAG in July 2009. As announced previously, 3SBio has distinctive rights to build up and commercialize Feraheme in China. Once approved by the SFDA, 3SBio will commence a multi-center randomized safety and efficacy study in China with approximately 200 CKD patients, measuring the mean switch in hemoglobin from baseline at Day time 35 after first dosage. Dr. Jing Lou, Chief Executive Officer of 3SBio comments: We are pleased with the timely submission of the Feraheme clinical trial application to the SFDA in China, representing a major milestone and our dedication to getting this innovative therapy to Chinese CKD patients in need. We look forward to working with the SFDA to ensure an efficient review process. Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals remarks: 3SBio may be the ideal partner to bring Feraheme to iron insufficiency anemia sufferers with chronic kidney disease in China.